Biocon & Bristol-Myers inaugurates R&D facility in BangaloreIllustrative image – not actual.

Syngene International, a subsidiary of Indian biotechnology major, Biocon and Bristol-Myers Squibb Company has inaugurated its fully dedicated research and development (R&D) facility for Bristol-Myers Squibb in Biocon Park, Bangalore.

The 20,000 sq. ft R&D facility at Biocon Park is devoted to help advance Bristol-Myers Squibb's work in discovery and early drug development, and is currently occupied by 270 researchers. The construction of the facility was started in March 2007 after Bristol Myers Squibb and Biocon entered into an agreement to develop integrated drug discovery and development capabilities at Syngene.

← All latest storiesBack to top →